References
1. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG.
Thrombocytopenia in patients in the medical intensive care unit:
Bleeding prevalence, transfusion requirements, and outcome. Crit
Care Med . 2002;30(8):1765-1771. doi:10.1097/00003246- 200208000-00015
2. Danese E, Montagnana M, Favaloro EJ, Lippi G. Drug-induced
thrombocytopenia: Mechanisms and laboratory diagnostics. Semin
Thromb Hemost . 2020;46(3):264-274. doi:10.1055/s-0039-1697930
3. Beaulieu C, Kurczewski L, Yajnik V. Cefepime challenge after
piperacillin/tazobactam-induced thrombocytopenia. J Thromb
Thrombolysis . 2019;48(1):167-170. doi:10.1007/s11239-019-01848-3
4. Großjohann B, Eichler P, Greinacher A, Santoso S, Kroll H.
Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic
anemia: Characterization of targets on platelets and red blood cells.Transfusion . 2004;44(7):1033-1040.
doi:10.1111/j.1537-2995.2004.03378.x
5. Chen S, Cooper N, Müller M, Bein G, Sachs UJ. Piperacillin-dependent
anti-platelet antibodies are a relevant, easy to confirm differential
diagnosis in patients with rapid-onset thrombocytopenia. Br J
Haematol . 2020;190(5):e320-e321. doi:10.1111/bjh.16899
6. Slaught M, Rasmussen M, Bougie D, Aster R. Immune thrombocytopenia
induced by beta-lactam antibiotics: Cross-reactions of responsible
antibodies with other beta-lactam drugs. Transfusion .
2021;61(5):1600-1608. doi:10.1111/trf.16295
7. Services H. Common Terminology Criteria for Adverse Events v3.0
(CTCAE). Princ Pract Clin Trial Med . Published online
2008:461-533. doi:10.1016/b978-0-12-373695-6.00022-3
8. Loo AS, Gerzenshtein L, Ison MG. Antimicrobial drug-induced
thrombocytopenia : A review of the literature. Published online
2012:818-829.
9. Chen H, Fan Z, Guo F, et al. Tazobactam and piperacillin-induced
thrombocytopenia: A case report. Exp Ther Med .
2016;11(4):1223-1226. doi:10.3892/etm.2016.3062
10. Shaik S, Kazi HA, Ender PT. Rapid-onset piperacillin-tazobactam
induced thrombocytopenia. J Pharm Pract . 2015;28(2):204-206.
doi:10.1177/0897190014566302
11. Nguyen VD, Tourigny JF, Roy R, Brouillette D. Rapid-onset
thrombocytopenia following piperacillin-tazobactam reexposure.Pharmacotherapy . 2015;35(12):e326-e330. doi:10.1002/phar.1675
12. Alzahrani M, Alrumaih I, Alhamad F, Abdel Warith A. Rapid onset
severe thrombocytopenia following reexposure to piperacillin-tazobactam:
report of two cases and review of the literature. Platelets .
2018;29(6):628-631. doi:10.1080/09537104.2018.1468025
13. Al-Sardi M, Ali H, Handoo F, AlJawad M. A rare case of rapid onset
thrombocytopenia induced by piperacillin/tazobactam in a liver
transplant recipient. Cureus . 2021;13(9):1-5.
doi:10.7759/cureus.18000
14. Kiliaki S. Piperacillin–Tazobactam-Induced Immune thrombocytopenia:
A case report. J Pharm Pract . Published online 2021:1-2.
doi:10.1177/08971900211048140
15. Stover KR, Barber KE, Wagner JL. Allergic reactions and
cross-reactivity potential with beta-lactamase inhibitors.Pharmacy . 2019;7(3):77. doi:10.3390/pharmacy7030077
16. Nguyen M-TH, Kaur P, Aster RH, Krishnan V. The first case report of
tazobactam induced thrombocytopenia. Blood .
2019;134(Supplement_1):4897-4897. doi:10.1182/blood-2019-126227
17. Kam T, Alexander M. Drug-induced immune thrombocytopenia. J
Pharm Pract . 2014;27(5):430-439. doi:10.1177/0897190014546099
18. Boyce K, Brar H, Stabler SN. Piperacillin/tazobactam-induced
immune-mediated thrombocytopenia in the intensive care unit. J
Clin Pharm Ther . 2016;41(6):730-732. doi:10.1111/jcpt.12458